Research programme: antibody-maytansinoid conjugates - Bayer HealthCareAlternative Names: Mesothelin-ADCs
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bayer HealthCare
- Class Antibodies; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Tubulin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours